Ortac 150 mg Tablet: Each film coated tablet contains Ranitidine Hydrochloride USP equivalent to 150 mg Ranitidine.
Ortac Injection: Each 2 ml Injection contains 55.80 mg Ranitidine Hydrochloride BP Equivalent to 50 mg Ranitidine BP
Gastric and duodenal ulcer, Prophylaxis and treatment of NSAID-induced ulcer, Gastro-esophageal reflux disease (GERD), Zollinger ellision syndrome, Acid related dyspepsia, Heartburn.
For patients known to have hypersensitivity to Ranitidine.
Dosage & Administration
Oral administration: 1 tablet twice daily or 2 tablets at night for 4-8 weeks.Parenteral Administration: In some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers or in patients unable to take oral medication, Ranitidine may be administered parenterally according to the following recommendation: IM Injection: 50 mg (2 ml) every 6 to 8 hours (no dilution is required). IV Injection: 50 mg (2 ml) every 6 to 8 hours. Dilute Ranitidine injection, 50 mg in compatible IV solution to a total volume of 20 ml and inject over a period of not less than 5 minutes. Parenteral administration may continue until oral feeding is commenced and if there is still a risk, oral Ranitidine may then commence.
Bradycardia in association with rapid administration of Ranitidine injection has been reported rarely, usually in patients with factors predisposing to cardiac rhythm disturbances.
Recommended rates of administration should not be exceeded.
There have been isolated reports of drug interactions which suggest that Ranitidine may affect the bioavailability of certain drugs (e.g., Ketoconazole) by some mechanisms as yet unidentified.
Ortac 50 mg tablet: Each Box containing 10x10\'s tablet in blister pack.Ortac Injection: Blister pack of 2x5\\\'s ampoules.